Investors

Investors

Inimmune is a fast moving innovative biotechnology company focused on the discovery and development of novel immunotherapeutics for allergy, autoimmunity and cancer.  Inimmune has a deep pipeline of early and late pre-clinical assets and a strong intellectual property position poised to change the landscape of immunotherapy.  The Inimmune team of industry professionals have an average of >15 years biotech/pharmaceutical experience and a long track record of success in bringing new vaccine adjuvants and immunotherapeutics to the marketplace.  The Inimmune management team is actively seeking partnerships and investors who share our vision to create and develop new safe and effective immunotherapeutics for the treatment of allergy, autoimmunity and cancer.

Inimmune's future is on the rise!

Inimmune’s future is on the rise!

Research Contracts and Collaborators 

Inimmune is currently working in close collaboration with the University of Montana and has a research contract with Kineta – biotech company based in Seattle, WA. Additionally, Inimmune has an active immunotherapy research collaboration with GlaxoSmithKline Pharmaceuticals.

Copyright © 2015 Inimmune